CA
NZ
UK
AU
IND
US
…
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 240.68M | 98.46M | 185.69M | 338.66M | 301.39M |
| Minority interest | - | 0.00M | 0.00M | -0.18M | 8.95M |
| Net income | 181.86M | 73.40M | 168.10M | 285.26M | 272.05M |
| Selling general administrative | 452.42M | 415.10M | 393.32M | 352.44M | 339.00M |
| Selling and marketing expenses | - | - | 69.55M | 25.94M | 33.77M |
| Gross profit | 799.07M | 790.27M | 769.73M | 769.82M | 756.50M |
| Reconciled depreciation | 97.36M | 109.90M | 111.71M | 107.24M | 101.07M |
| Ebit | 246.09M | 106.97M | 201.43M | 298.94M | 296.59M |
| Ebitda | 343.44M | 216.88M | 313.14M | 406.18M | 397.66M |
| Depreciation and amortization | 97.36M | 109.90M | 111.71M | 107.24M | 101.07M |
| Non operating income net other | - | - | - | 50.93M | 16.11M |
| Operating income | 251.89M | 102.25M | 206.69M | 298.94M | 296.59M |
| Other operating expenses | 963.15M | 1117.38M | 952.37M | 837.76M | 809.01M |
| Interest expense | 5.41M | 8.51M | 15.74M | -11.21M | 11.31M |
| Tax provision | 58.82M | 25.06M | 17.58M | 53.22M | 38.29M |
| Interest income | 4.22M | 3.89M | 3.32M | 3.41M | 0.79M |
| Net interest income | -5.41M | -4.62M | -12.41M | -7.80M | -10.52M |
| Income tax expense | 58.82M | 25.06M | 17.58M | 53.22M | 38.29M |
| Total revenue | 1215.04M | 1219.63M | 1159.06M | 1136.70M | 1105.60M |
| Total operating expenses | 547.18M | 688.02M | 563.04M | 470.87M | 459.91M |
| Cost of revenue | 415.97M | 429.36M | 389.33M | 366.89M | 349.10M |
| Total other income expense net | -11.21M | -3.79M | -21.00M | 39.72M | 4.80M |
| Net income from continuing ops | 181.86M | 73.40M | 168.10M | 285.44M | 263.10M |
| Net income applicable to common shares | - | - | - | 285.26M | 272.05M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 2678.99M | 2557.87M | 2703.87M | 2638.69M | 2294.80M |
| Intangible assets | 303.46M | 365.60M | 507.08M | 534.64M | 531.52M |
| Other current assets | 63.45M | 49.79M | 43.43M | 27.07M | 22.86M |
| Total liab | 570.77M | 639.06M | 635.02M | 672.18M | 593.79M |
| Total stockholder equity | 2108.22M | 1918.81M | 2068.85M | 1966.52M | 1701.01M |
| Deferred long term liab | - | - | - | 88.98M | 98.99M |
| Other current liab | 85.99M | 93.10M | 76.86M | 16.93M | 14.48M |
| Common stock | 1.56M | 1.55M | 1.58M | 1.58M | 0.39M |
| Capital stock | 1.56M | 1.55M | 1.58M | 1.58M | 0.39M |
| Retained earnings | 1144.19M | 1066.05M | 1325.25M | 1309.46M | 1122.92M |
| Other liab | - | - | - | 99.90M | 116.23M |
| Good will | 975.36M | 980.93M | 972.66M | 872.74M | 822.10M |
| Other assets | - | - | - | 12.59M | 46.83M |
| Cash | 264.71M | 162.19M | 151.79M | 180.57M | 172.57M |
| Total current liabilities | 163.70M | 175.85M | 159.38M | 128.51M | 176.02M |
| Current deferred revenue | 36.07M | 32.57M | 27.93M | 23.07M | 23.41M |
| Net debt | 24.38M | 281.87M | 267.75M | 274.39M | 153.40M |
| Short term debt | 14.94M | 14.10M | 12.92M | 11.20M | 24.43M |
| Short long term debt | - | - | - | - | 12.50M |
| Short long term debt total | 289.09M | 444.06M | 419.54M | 454.96M | 325.97M |
| Other stockholder equity | 1033.05M | 911.09M | 820.34M | 721.54M | 652.90M |
| Property plant equipment | - | - | - | 226.20M | 288.80M |
| Total current assets | 744.40M | 608.30M | 617.42M | 621.48M | 605.56M |
| Long term investments | 245.83M | 250.98M | 242.34M | - | - |
| Net tangible assets | - | - | - | 652.90M | 347.39M |
| Short term investments | - | 0.00M | 1.07M | 23.74M | 74.46M |
| Net receivables | 220.50M | 206.88M | 241.39M | 218.47M | 194.55M |
| Long term debt | 200.00M | 346.00M | 319.00M | 350.00M | 243.41M |
| Inventory | 195.74M | 189.45M | 179.73M | 171.64M | 141.12M |
| Accounts payable | 26.70M | 25.31M | 37.97M | 77.31M | 113.70M |
| Noncontrolling interest in consolidated entity | - | - | - | - | -0.76M |
| Accumulated other comprehensive income | -70.58M | -59.88M | -78.32M | -66.06M | -75.20M |
| Common stock total equity | - | - | - | 1.58M | 0.39M |
| Retained earnings total equity | - | - | - | 1309.46M | 1122.92M |
| Non currrent assets other | 10.95M | 22.63M | 21.93M | 285.30M | -52.17M |
| Non current assets total | 1934.59M | 1949.57M | 2086.45M | 2017.21M | 1689.25M |
| Capital lease obligations | 89.09M | 98.06M | 100.54M | 104.97M | 70.06M |
| Long term debt total | - | - | - | 350.00M | 243.41M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | 0.00M | -35.18M | -203.03M | -265.65M | -96.85M |
| Change to liabilities | - | - | - | -34.96M | 12.74M |
| Total cashflows from investing activities | -18.19M | -35.18M | -203.03M | -265.65M | -96.85M |
| Net borrowings | -146.00M | 27.00M | -31.00M | 94.00M | -85.50M |
| Total cash from financing activities | -169.11M | -253.91M | -122.40M | 22.62M | -242.85M |
| Change to operating activities | - | - | - | -29.14M | 4.68M |
| Net income | 181.86M | 73.40M | 168.07M | 285.44M | 263.10M |
| Change in cash | 102.53M | 10.39M | -28.78M | 8.00M | -26.52M |
| Begin period cash flow | 162.19M | 151.79M | 180.57M | 172.57M | 199.09M |
| End period cash flow | 264.71M | 162.19M | 151.79M | 180.57M | 172.57M |
| Total cash from operating activities | 292.07M | 287.56M | 298.98M | 254.39M | 325.27M |
| Depreciation | 97.36M | 109.90M | 111.71M | 107.24M | 101.07M |
| Other cashflows from investing activities | 10.66M | 15.26M | 7.00M | -27.96M | -51.94M |
| Dividends paid | 49.92M | 50.39M | 50.42M | 50.28M | 50.19M |
| Change to inventory | -8.23M | -18.14M | -14.21M | 0.40M | -32.01M |
| Change to account receivables | -10.79M | 42.60M | -31.13M | -20.87M | -57.60M |
| Sale purchase of stock | -41.67M | -275.73M | -80.04M | -19.56M | -160.95M |
| Other cashflows from financing activities | -12.14M | 45.22M | 39.06M | 92.46M | 143.78M |
| Change to netincome | - | - | - | -37.20M | -47.85M |
| Capital expenditures | 28.85M | 31.01M | 62.88M | 38.24M | 44.91M |
| Change receivables | - | - | - | -20.87M | -57.60M |
| Cash flows other operating | - | - | - | -15.10M | -39.14M |
| Cash and cash equivalents changes | - | - | - | 11.36M | -14.43M |
| Change in working capital | -41.30M | 11.54M | -10.11M | -48.19M | -69.52M |
| Stock based compensation | 41.37M | 40.83M | 38.04M | 39.23M | 42.18M |
| Other non cash items | -0.41M | 102.99M | 30.71M | -99.76M | -18.38M |
| Free cash flow | 263.22M | 256.55M | 236.10M | 216.15M | 280.36M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TECH Bio-Techne Corp |
-0.05 0.07% |
72.66 | 62.36 | 34.48 | 9.34 | 5.38 | 9.35 | 32.67 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
614 McKinley Place N.E., Minneapolis, MN, United States, 55413
612 379 8854
3000
| Name | Title | Year Born |
|---|---|---|
| Mr. Charles R. Kummeth | CEO, Pres & Director | 1960 |
| Mr. James T. Hippel | Exec. VP of Fin. & CFO | 1971 |
| Ms. Brenda S. Furlow J.D. | Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer | 1958 |
| Mr. Kim Kelderman | Pres of Diagnostics & Genomics | 1967 |
| Mr. William A. Geist | Pres of Protein Sciences Segment | 1970 |
| David Clair | Sr. Director of Investor Relations & Corp. Devel. | NA |
| Mr. Gerry Andros | VP of Sales and Marketing | NA |
| Mr. Robert M. Gavin | VP of Corp. Devel. | 1968 |
| Ms. Brenda S. Everson | Sr. VP & Chief HR Officer | NA |
| Mr. Luca Cicchetti | Managing Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...